Frontierby eninvs

Language: EN · RU

← Region

Cipla INR

At a glance: strengths & risks
✓Net cash balance sheet✗Profit falling (-26%)✗Margins compressing (29%→23%)

Sector: Pharmaceuticals

IN_CIPLA

Price chart

1 423 INRDay -0.04%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
1 423 INR · -0.04%
Market cap
1149.6 bn INR

Growth

Δ revenue y/y
3.5%
Δ EBITDA y/y
-32.9%

Multiples

P/E (LTM)
29.6x
3y avg: 26.2x
P/B (FY)
3.3x
P/E (ann.)
36.4x
EV/EBITDA (LTM)
19.3x
3y avg: 17.6x
EV/EBITDA (ann.)
23.9x

Cash return

Dividend yield
0.9%
FCF yield (LTM)
0.7%

Value creation

fundamental value/yr, % of market cap
Value created / year
-39.1%
↓ details

Liquidity

Daily turnover (listing)
56.4 mln INR

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in B INR, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB INROperating profitB INRD&AB INREBITDAB INRNet profitB INROperating CFB INRCapex + M&AB INRAssetsB INREquityB INRROE (annualized)Net debtB INRSource
2026-06-30Q2 2026 (3M)PARTIAL70.8
y/y 3.5%
8.9
y/y -41.8%
3.0
y/y 20.4%
11.9
y/y -32.9%
7.9
y/y -39.2%
———
y/y —
345.2
y/y 10.3%
9.2%≈ -7.6—
2026-03-31FY 2026 (12M)OK—
y/y 2.1%
—
y/y -21.1%
—
y/y 8.9%
—
y/y -17.0%
—
y/y -26.4%
——425.0
y/y 13.7%
344.3
y/y 10.4%
11.5%-7.6—
2025-12-31Q4 2025 (3M)PARTIAL69.6
y/y 0.0%
9.8
y/y -42.9%
-9.3
y/y —
12.6
y/y -26.6%
6.8
y/y -57.0%
———
y/y —
330.2
y/y 16.1%
2.7%≈ -7.0—
2025-09-30Q3 2025 (3M)OK74.5
y/y 7.0%
16.0
y/y -1.0%
9.6
y/y —
28.1
y/y 74.2%
13.5
y/y 3.7%
——401.6
y/y 15.9%
330.2
y/y 16.1%
16.8%-7.0Link
2025-06-30Q2 2025 (3M)PARTIAL68.4
y/y 3.2%
15.3
y/y 3.8%
2.5
y/y —
17.8
y/y 21.0%
13.0
y/y 10.2%
———
y/y —
312.9
y/y 16.7%
16.6%≈ -5.0—
2025-03-31FY 2025 (12M)OK—
y/y 6.7%
—
y/y 14.4%
—
y/y -5.3%
—
y/y 11.2%
—
y/y 27.9%
——373.9
y/y 14.3%
311.9
y/y 16.8%
17.7%-5.0—
2024-12-31Q4 2024 (3M)PARTIAL69.6
y/y 7.0%
17.1
y/y 12.9%
—
y/y —
17.1
y/y 12.9%
15.7
y/y 48.7%
———
y/y —
284.6
y/y 13.4%
7.4%≈ -7.6Link
2024-09-30Q3 2024 (3M)OK69.6
y/y 5.6%
16.1
y/y 11.8%
—
y/y —
16.1
y/y 11.8%
13.0
y/y 15.2%
——346.6
y/y 10.4%
284.6
y/y 13.4%
18.9%-7.6Link
2024-06-30Q2 2024 (3M)PARTIAL66.2
y/y —
14.7
y/y —
—
y/y —
14.7
y/y —
11.8
y/y —
———
y/y —
268.0
y/y —
17.6%≈ -3.9Link
2024-03-31FY 2024 (12M)OK—
y/y 13.2%
—
y/y 33.6%
—
y/y 3.1%
—
y/y 27.4%
—
y/y 47.1%
——327.2
y/y 11.0%
267.1
y/y 14.1%
15.9%-3.9—
2023-12-31Q4 2023 (3M)PARTIAL65.1
y/y —
15.1
y/y —
—
y/y —
15.1
y/y —
10.6
y/y —
———
y/y —
251.0
y/y —
5.6%≈ -1.1Link
2023-09-30Q3 2023 (3M)OK65.9
y/y —
14.4
y/y —
—
y/y —
14.4
y/y —
11.3
y/y —
——313.8
y/y —
251.0
y/y —
18.7%≈ -1.1Link
2023-03-31FY 2023 (12M)OK224.7
y/y —
40.2
y/y —
10.2
y/y —
50.4
y/y —
28.0
y/y —
32.4-11.8294.6
y/y —
234.1
y/y —
—-1.1—

Revenue & EBITDA

RevenueEBITDA

Quarterly values (INR mln)

020 00040 00060 00080 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Year-over-year change

-50%0%50%2024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Cash flow

Net debt / cash (INR mln)

-8 000-6 000-4 000-2 00002024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q22026 q4

Profit and cash

Profit is cash-backed
In a typical year of 2022–2026 operating cash flow came to 1.02x of reported net profit; after capex, 0.68x.
year20222023202420252026
cash flow / profit1.32x1.16x1.00x0.95x1.02x
accruals, % of assets—-1.5%-0.0%0.7%-0.1%
net debt / EBITDA -0.1x · capex 1.5x of depreciation
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -39.1%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30)
= (11 923 − 17 781) × 5.25
-30 736
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (1 149 575 + -7 602) ÷ 62 554
18.3x
3. Target multiple
(Current EV/EBITDA + 11) ÷ 2
= (18.3 + 11) ÷ 2
14.6x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= 2 637 + 0 + 0 − 0
0
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (-30 736 × 14.6 + 0) ÷ 1 149 575
-39.1%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • FCF (LTM) approximated by latest FY (ended 2026-03-31, before the latest reported period 2026-06-30)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only
  • net-cash rise stripped: net debt fell while EBITDA declined and no share dilution measured (likely equity raise / recapitalisation)

Revenue growth & acceleration

Growth decelerating ▼
Last-year revenue growth +2% vs +7% the year before — a -4.6 pp move. 3-year CAGR +7%.
revenue growth by year: 2024 +13% · 2025 +7% · 2026 +2%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-06-0513 INREx-dividend: 13 INR per sharePaidYahoo Finance (ex-div)
2025-06-2716 INREx-dividend: 16 INR per sharePaidYahoo Finance (ex-div)
2024-08-0213 INREx-dividend: 13 INR per sharePaidYahoo Finance (ex-div)
2023-07-218.5 INREx-dividend: 8.5 INR per sharePaidYahoo Finance (ex-div)
2022-08-085 INREx-dividend: 5 INR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Cipla — from primary filings.

Frequently asked questions

What is Cipla's P/E ratio?
Cipla trades at a P/E of 29.6x (price to trailing 12-month earnings).
What is Cipla's EV/EBITDA?
Cipla trades at 19.3x EV/EBITDA.
What is Cipla's P/B ratio?
Cipla trades at a P/B of 3.3x.
What is Cipla's dividend yield?
Cipla's trailing 12-month dividend yield is 0.9%.
What is Cipla's return on equity (ROE)?
Cipla's ROE is 9.2%.
What is Cipla's market capitalization?
Cipla's market cap is 1149.6 bn INR.

See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map